Genome-Wide/NN
Association/NN
Study/NN
Identifies/NNS
Candidate/NN
Loci/NNS
Associated/VBN
with/IN
Platelet/NN
Count/NN
in/IN
Koreans/NNS
./.
====================
Platelets/NNS
are/VBP
derived/VBN
from/IN
the/DT
fragments/NNS
that/WDT
are/VBP
formed/VBN
from/IN
the/DT
cytoplasm/NN
of/IN
bone/NN
marrow/NN
megakaryocytes-small/JJ
irregularly/RB
shaped/VBD
anuclear/JJ
cells/NNS
./.
====================
Platelets/NNS
respond/VBP
to/TO
vascular/JJ
damage/NN
,/,
contracts/VBZ
blood/NN
vessels/NNS
,/,
and/CC
attaches/NNS
to/TO
the/DT
damaged/VBN
region/NN
,/,
thereby/RB
stopping/VBG
bleeding/VBG
,/,
together/RB
with/IN
the/DT
action/NN
of/IN
blood/NN
coagulation/NN
factors/NNS
./.
====================
Platelet/NN
activation/NN
is/VBZ
known/VBN
to/TO
affect/VB
genes/NNS
associated/VBN
with/IN
vascular/JJ
risk/NN
factors/NNS
,/,
as/IN
well/RB
as/IN
with/IN
arteriosclerosis/NN
and/CC
myocardial/JJ
infarction/NN
./.
====================
Here/RB
,/,
we/PRP
performed/VBD
a/DT
genome-wide/JJ
association/NN
study/NN
with/IN
352,228/CD
single-nucleotide/JJ
polymorphisms/NNS
typed/VBN
in/IN
8,842/CD
subjects/NNS
of/IN
the/DT
Korea/NN
Association/NN
Resource/NN
(/(
KARE/NN
)/)
project/VBP
and/CC
replicated/VBD
the/DT
results/NNS
in/IN
7,861/CD
subjects/NNS
from/IN
an/DT
independent/JJ
population/NN
./.
====================
We/PRP
identified/VBD
genetic/JJ
associations/NNS
between/IN
platelet/NN
count/NN
and/CC
common/JJ
variants/NNS
nearby/JJ
chromosome/NN
4p16.1/CD
(/(
p/NN
=/JJ
1.46/CD
×/CD
10-10/CD
,/,
in/IN
the/DT
KIAA0232/NN
gene/NN
)/)
,/,
6p21/NN
(/(
p/NN
=/JJ
1.36/CD
×/CD
10-7/CD
,/,
in/IN
the/DT
BAK1/NN
gene/NN
)/)
,/,
and/CC
12q24.12/NN
(/(
p/NN
=/JJ
1.11/CD
×/CD
10-15/CD
,/,
in/IN
the/DT
SH2B3/NN
gene/NN
)/)
./.
====================
Our/PRP$
results/NNS
illustrate/VBP
the/DT
value/NN
of/IN
large-scale/JJ
discovery/NN
and/CC
a/DT
focus/NN
for/IN
several/JJ
novel/JJ
research/NN
avenues/NNS
./.
====================
Blood/NN
circulates/NNS
through/IN
the/DT
body/NN
,/,
affecting/VBG
the/DT
tissues/NNS
by/IN
delivering/VBG
oxygen/NN
and/CC
nutrients/NNS
responsible/JJ
for/IN
tissue/NN
viability/NN
./.
====================
The/DT
size/NN
,/,
number/NN
,/,
and/CC
concentration/NN
of/IN
a/DT
cell/NN
in/IN
the/DT
blood/NN
vary/VBP
among/IN
populations/NNS
,/,
and/CC
these/DT
have/VBP
been/VBN
regarded/VBN
as/IN
factors/NNS
influencing/VBG
various/JJ
disorders/NNS
,/,
such/JJ
as/IN
erythrocytosis/NN
,/,
anemia/NN
,/,
hypertension/NN
,/,
and/CC
cardiovascular/JJ
diseases/NNS
./.
====================
During/IN
the/DT
last/JJ
2/CD
decades/NNS
,/,
genetic/JJ
studies/NNS
have/VBP
revealed/VBN
that/IN
there/EX
exists/VBZ
a/DT
genetic/JJ
effect/NN
on/IN
several/JJ
hematologic/JJ
variables/NNS
./.
====================
Moreover/RB
,/,
previous/JJ
studies/NNS
reported/VBD
that/IN
genetic/JJ
factors/NNS
strongly/RB
influence/VBP
the/DT
variation/NN
in/IN
the/DT
counts/NNS
and/CC
size/NN
of/IN
blood/NN
cells/NNS
[/(
1/CD
,/,
2/CD
]/)
./.
====================
Although/IN
a/DT
few/JJ
genes/NNS
are/VBP
known/VBN
to/TO
affect/VB
hematologic/JJ
traits/VBZ
,/,
the/DT
physiological/JJ
mechanisms/NNS
underlying/VBG
the/DT
traits/NNS
are/VBP
largely/RB
unrevealed/JJ
./.
====================
Platelets/NNS
are/VBP
anuclear/JJ
cytoplasmic/JJ
fragments/NNS
that/WDT
play/VBP
a/DT
key/JJ
role/NN
in/IN
maintaining/VBG
primary/JJ
adhesion/NN
,/,
aggregation/NN
,/,
and/CC
secretion/NN
and/CC
providing/VBG
procoagulant/JJ
surface/NN
and/CC
clot/NN
retraction/NN
./.
====================
The/DT
primary/JJ
functions/NNS
of/IN
a/DT
platelet/NN
count/NN
are/VBP
to/TO
assist/VB
in/IN
the/DT
diagnosis/NN
of/IN
bleeding/VBG
disorders/NNS
and/CC
to/TO
monitor/VB
patients/NNS
who/WP
are/VBP
being/VBG
treated/VBN
for/IN
any/DT
disease/NN
involving/VBG
bone/NN
marrow/NN
failure/NN
./.
====================
Low/JJ
platelet/NN
counts/NNS
or/CC
abnormally/RB
shaped/VBD
platelets/NNS
are/VBP
associated/VBN
with/IN
bleeding/VBG
disorders/NNS
,/,
whereas/IN
high/JJ
platelet/NN
counts/NNS
sometimes/RB
indicate/VBP
disorders/NNS
of/IN
the/DT
bone/NN
marrow/NN
./.
====================
Platelet/NN
activation/NN
is/VBZ
known/VBN
to/TO
affect/VB
genes/NNS
associated/VBN
with/IN
vascular/JJ
risk/NN
factors/NNS
,/,
as/IN
well/RB
as/IN
with/IN
arteriosclerosis/NN
and/CC
myocardial/JJ
infarction/NN
./.
====================
Platelet/NN
count/NN
is/VBZ
a/DT
readily/RB
available/JJ
laboratory/NN
test/NN
and/CC
has/VBZ
been/VBN
associated/VBN
with/IN
different/JJ
clinical/JJ
and/CC
epidemiologic/JJ
factors/NNS
and/CC
are/VBP
tightly/RB
regulated/VBN
and/CC
inversely/RB
correlated/VBN
in/IN
the/DT
healthy/JJ
population/NN
[/(
3/CD
]/)
./.
====================
Furthermore/RB
,/,
because/IN
platelet/NN
count/NN
differs/VBZ
between/IN
inter-ethnic/JJ
groups/NNS
,/,
gender/NN
and/CC
ethnicity/NN
should/MD
be/VB
important/JJ
considerations/NNS
for/IN
a/DT
platelet/NN
count/NN
study/NN
[/(
4/CD
]/)
./.
====================
Recently/RB
,/,
genome-wide/NN
association/NN
studies/NNS
(/(
GWASs/NNS
)/)
for/IN
hematological/JJ
traits/VBZ
have/VBP
been/VBN
reported/VBN
[/(
5/CD
,/,
6/CD
,/,
7/CD
]/)
./.
====================
Particularly/RB
,/,
68/CD
single-nucleotide/JJ
polymorphisms/NNS
(/(
SNPs/NNS
)/)
associated/VBN
with/IN
platelet/NN
count/NN
were/VBD
identified/VBN
by/IN
a/DT
GWAS/JJ
[/(
8/CD
]/)
./.
====================
However/RB
,/,
although/IN
the/DT
heritability/NN
of/IN
variation/NN
in/IN
platelet/NN
count/NN
ranged/VBD
from/IN
54/CD
%/NN
to/TO
more/RBR
than/IN
80/CD
%/NN
[/(
9/CD
,/,
10/CD
,/,
11/CD
]/)
,/,
the/DT
genetic/JJ
variants/NNS
reported/VBD
to/TO
date/NN
explain/VBP
only/RB
a/DT
small/JJ
fraction/NN
of/IN
the/DT
heritability/NN
in/IN
platelet/NN
count/NN
[/(
12/CD
]/)
./.
====================
Therefore/RB
,/,
new/JJ
studies/NNS
have/VBP
opportunities/NNS
to/TO
unveil/VB
additional/JJ
genetic/JJ
variants/NNS
for/IN
explaining/VBG
missing/VBG
heritability/NN
[/(
12/CD
]/)
./.
====================
In/IN
this/DT
study/NN
,/,
we/PRP
conducted/VBD
a/DT
GWAS/JJ
to/TO
find/VB
a/DT
contribution/NN
of/IN
the/DT
genetic/JJ
basis/NN
on/IN
hematologic/JJ
variables/NNS
,/,
such/JJ
as/IN
platelet/NN
count/NN
,/,
in/IN
Koreans/NNS
./.
====================
Subjects/NNS
====================
We/PRP
conducted/VBD
a/DT
GWAS/JJ
using/VBG
individuals/NNS
sampled/JJ
from/IN
a/DT
part/NN
of/IN
the/DT
Korean/JJ
Genome/NN
Epidemiology/NN
Study/NN
(/(
KoGES/NN
)/)
./.
====================
The/DT
study/NN
subjects/NNS
were/VBD
recruited/VBN
from/IN
population-based/JJ
cohorts/NNS
in/IN
the/DT
regions/NNS
of/IN
Anseong/JJ
and/CC
Ansan/NN
./.
====================
The/DT
standardized/VBN
examinations/NNS
applied/VBD
in/IN
this/DT
survey/NN
included/VBD
10,038/CD
participants/NNS
aged/JJ
40/CD
to/TO
69/CD
years/NNS
./.
====================
Subjects/NNS
for/IN
the/DT
replication/NN
study/NN
were/VBD
recruited/VBN
from/IN
the/DT
Health2/NN
cohorts/NNS
,/,
another/DT
population-based/JJ
cohort/NN
comprising/VBG
the/DT
Wonju/NN
,/,
Pyeongchang/NNP
,/,
Gangneung/JJ
,/,
Geumsan/NNP
,/,
and/CC
Naju/NN
regions/NNS
in/IN
Korea/NN
./.
====================
Among/IN
a/DT
total/JJ
of/IN
8,500/CD
participants/NNS
within/IN
the/DT
Health2/NN
cohort/NN
,/,
7,861/CD
subjects/NNS
were/VBD
selected/VBN
for/IN
the/DT
replication/NN
analysis/NN
based/VBN
on/IN
their/PRP$
age/NN
and/CC
information/NN
about/IN
concomitant/JJ
disease/NN
and/CC
medication/NN
[/(
13/CD
]/)
./.
====================
Platelet/NN
counts/NNS
and/CC
genotyping/VBG
====================
Peripheral/JJ
blood/NN
was/VBD
isolated/VBN
by/IN
using/VBG
the/DT
G-DEX/NN
TM/NN
IIb/NN
DNA/NN
Extraction/NN
Kit/NN
(/(
iNtRON/NN
Biotechnology/NN
,/,
Seongnam/JJ
,/,
Korea/NN
)/)
./.
====================
Platelet/NN
count/NN
was/VBD
measured/VBN
using/VBG
an/DT
ADVIA/NN
120/CD
(/(
Bayer/NN
,/,
Tarrytown/VBN
,/,
NY/NN
,/,
USA/NN
)/)
./.
====================
Genomic/JJ
DNA/NN
,/,
genotyped/VBD
on/IN
the/DT
Affymetrix/JJ
Genome-Wide/NN
Human/JJ
SNP/NN
array/NN
5.0/CD
(/(
Affymetrix/JJ
,/,
Inc./NNP
,/,
Santa/NN
Clara/NN
,/,
CA/NNP
,/,
USA/NNP
)/)
,/,
was/VBD
isolated/VBN
from/IN
peripheral/JJ
blood/NN
drawn/VBN
from/IN
Anseong/JJ
and/CC
Ansan/NN
cohort/NN
participants/NNS
./.
====================
Of/IN
9,603/CD
genotyped/VBD
samples/NNS
,/,
we/PRP
excluded/VBD
samples/NNS
with/IN
high/JJ
heterozygosity/NN
(/(
>/JJR
30/CD
%/NN
,/,
n/NN
=/JJ
11/CD
)/)
and/CC
gender/NN
inconsistencies/VBZ
(/(
n/NN
=/JJ
41/CD
)/)
./.
====================
Also/RB
,/,
individuals/NNS
who/WP
had/VBD
developed/VBN
any/DT
kind/JJ
of/IN
cancer/NN
(/(
n/NN
=/JJ
101/CD
)/)
were/VBD
excluded/VBN
from/IN
subsequent/JJ
analyses/NNS
./.
====================
To/TO
examine/VB
population/NN
stratification/NN
overall/JJ
,/,
related/JJ
or/CC
identical/JJ
individuals/NNS
with/IN
higher/JJR
values/NNS
than/IN
first-degree/JJ
relatives/VBZ
of/IN
Korean/JJ
sib-pair/JJ
samples/NNS
were/VBD
also/RB
excluded/VBN
according/VBG
to/TO
average/VB
pair-wise/JJ
identity-by-state/VBP
(/(
IBS/NN
)/)
values/NNS
(/(
>/JJR
0.80/CD
,/,
n/NN
=/JJ
608/CD
)/)
./.
====================
The/DT
methods/NNS
to/TO
estimate/VB
heterozygosity/NN
and/CC
IBS/NN
have/VBP
been/VBN
described/VBN
elsewhere/VBP
[/(
13/CD
]/)
./.
====================
SNP/NN
markers/NNS
with/IN
a/DT
high/JJ
missing/VBG
genotype/NN
rate/NN
(/(
>/JJR
5/CD
%/NN
)/)
,/,
low/JJ
minor/JJ
allele/NN
frequency/NN
(/(
MAF/NN
,/,
</JJR
0.01/CD
)/)
,/,
and/CC
significant/JJ
deviation/NN
from/IN
Hardy-Weinberg/JJ
equilibrium/NN
(/(
p/NN
</JJR
1/CD
×/NN
10-6/CD
)/)
were/VBD
excluded/VBN
./.
====================
Consequently/RB
,/,
a/DT
total/JJ
of/IN
352,228/CD
markers/NNS
were/VBD
used/VBN
for/IN
the/DT
GWAS/NN
./.
====================
For/IN
the/DT
replication/NN
analysis/NN
,/,
19/CD
SNPs/NNS
of/IN
the/DT
Health2/NN
population/NN
,/,
comprising/VBG
7,861/CD
participants/NNS
,/,
were/VBD
genotyped/VBN
by/IN
GoldenGate/NN
assay/NN
(/(
Illumina/NN
Inc./NNP
,/,
San/NNP
Diego/NN
,/,
CA/NNP
,/,
USA/NNP
)/)
./.
====================
Imputation/NN
====================
Imputation/NN
was/VBD
carried/VBN
out/RP
by/IN
using/VBG
the/DT
IMPUTE/NN
program/NN
version/NN
1/CD
(/(
http/NN
:/:
//mathgen.stats.ox.ac.uk/impute/impute.html/NN
)/)
[/(
14/CD
,/,
15/CD
]/)
./.
====================
On/IN
the/DT
basis/NN
of/IN
NCBI/NN
,/,
build/JJ
36/CD
and/CC
dbSNP/NN
,/,
build/JJ
126/CD
,/,
we/PRP
initially/RB
used/VBN
90/CD
individuals/NNS
from/IN
Japanese/JJ
in/IN
Tokyo/JJ
,/,
Japan/NNP
(/(
JPT/NN
)/)
and/CC
Han/JJ
Chinese/JJ
in/IN
Beijing/VBG
,/,
China/NNP
(/(
CHB/NN
)/)
founders/VBZ
in/IN
HapMap/NN
as/IN
a/DT
reference/RB
panel/NN
,/,
comprising/VBG
3.99/CD
million/NN
SNPs/NNS
(/(
release/NN
22/CD
)/)
./.
====================
After/IN
removing/VBG
SNPs/NNS
with/IN
an/DT
MAF/NN
</JJR
0.01/CD
and/CC
an/DT
SNP/NN
missing/VBG
rate/NN
>/JJR
0.05/CD
,/,
we/PRP
combined/VBD
the/DT
remaining/VBG
1.8/CD
million/NN
imputed/JJ
SNPs/NNS
with/IN
the/DT
directly/RB
typed/VBN
Korea/NN
Association/NN
Resource/NN
(/(
KARE/NN
)/)
SNPs/NNS
for/IN
the/DT
association/NN
analyses/NNS
./.
====================
Association/NN
analyses/NNS
for/IN
imputed/JJ
SNPs/NNS
were/VBD
carried/VBN
out/RP
by/IN
the/DT
SNPTEST/NN
program/NN
(/(
http/NN
:/:
//www.stats.ox.ac.uk/~marchini/software/gwas/snptest.html/NN
)/)
./.
====================
Statistical/JJ
analysis/NN
====================
Association/NN
analysis/NN
of/IN
platelet/NN
trait/NN
with/IN
genotypes/NNS
was/VBD
performed/VBN
using/VBG
a/DT
linear/JJ
regression/NN
model/NN
,/,
adjusting/VBG
for/IN
age/NN
,/,
sex/NN
,/,
and/CC
recruitment/NN
area/NN
./.
====================
Analyses/NNS
were/VBD
performed/VBN
with/IN
the/DT
software/JJ
PLINK/NN
(/(
http/NN
:/:
//pngu.mgh.harvard.edu/~purcell/plink/NN
)/)
,/,
SAS/NN
version/NN
9.1/CD
(/(
SAS/NN
Inc./NNP
,/,
Cary/NN
,/,
NC/NN
,/,
USA/NNP
)/)
,/,
and/CC
R/NN
statistics/NNS
package/NN
version/NN
2.7.1/CD
./.
====================
The/DT
KARE/NN
GWAS/NN
and/CC
replication/NN
study/NN
were/VBD
combined/VBN
by/IN
an/DT
inverse-variance/NN
meta-analysis/NN
method/NN
,/,
assuming/VBG
fixed/JJ
effects/NNS
,/,
with/IN
Cochran/NN
's/POS
Q/NN
test/NN
to/TO
assess/VB
between-study/IN
heterogeneity/NN
[/(
16/CD
]/)
./.
====================
Regional/JJ
plots/NNS
were/VBD
generated/VBN
using/VBG
LocusZoom/JJ
[/(
17/CD
]/)
./.
====================
Characteristics/NNS
of/IN
the/DT
study/NN
participants/NNS
,/,
including/VBG
age/NN
,/,
sex/NN
,/,
and/CC
trait/VBP
summaries/VBZ
,/,
are/VBP
presented/VBN
in/IN
Table/JJ
1/CD
./.
====================
Quantile-quantile/JJ
analysis/NN
of/IN
2-d.f/JJ
./.
====================
logistic/JJ
regression/NN
statistics/NNS
for/IN
the/DT
comparison/NN
of/IN
genotype/NN
frequencies/NNS
in/IN
the/DT
cohorts/NNS
confirmed/VBD
the/DT
genetic/JJ
homogeneity/NN
of/IN
these/DT
two/CD
components/NNS
of/IN
the/DT
KARE/NN
study/NN
population/NN
(/(
Fig/NN
./.
====================
1/CD
)/)
./.
====================
We/PRP
observed/VBD
significant/JJ
SNPs/NNS
by/IN
applying/VBG
a/DT
Bonferroni/JJ
adjustment/JJ
cut-off/JJ
with/IN
a/DT
combined/JJ
p-value/NN
</JJR
1.0/CD
×/CD
10-7/CD
./.
====================
The/DT
GWAS/NN
identified/VBN
several/JJ
genomic/JJ
locations/NNS
as/IN
potentially/RB
associated/VBN
with/IN
platelet/NN
count/NN
(/(
Fig/NN
./.
====================
2/CD
)/)
./.
====================
In/IN
a/DT
follow-up/JJ
examination/NN
of/IN
the/DT
Health2/NN
cohort/NN
,/,
we/PRP
examined/VBD
7,861/CD
selected/VBN
from/IN
8,500/CD
participants/NNS
(/(
aged/JJ
,/,
40/CD
to/TO
69/CD
years/NNS
)/)
./.
====================
We/PRP
confirmed/VBD
3/CD
replicated/VBD
signals/NNS
,/,
of/IN
which/WDT
3/CD
signals/NNS
,/,
replicating/VBG
previously/RB
documented/VBN
reports/NNS
,/,
and/CC
one/CD
novel/JJ
locus/NN
were/VBD
discovered/VBN
./.
====================
We/PRP
observed/VBD
3/CD
independent/JJ
signals/NNS
with/IN
p/NN
</JJR
10-5/CD
for/IN
platelet/NN
counts/NNS
./.
====================
Table/JJ
2/CD
and/CC
Fig/NN
./.
====================
3/CD
show/VBP
results/NNS
for/IN
three/CD
regions/NNS
that/IN
had/VBD
combined/VBN
genomewide/NN
significant/JJ
evidence/NN
for/IN
association/NN
with/IN
platelet/NN
count/NN
in/IN
the/DT
KARE/NN
GWAS/NN
and/CC
replication/NN
samples/NNS
./.
====================
For/IN
platelet/NN
counts/NNS
,/,
the/DT
strongest/JJS
evidence/NN
for/IN
association/NN
was/VBD
at/IN
12q24/CD
(/(
rs739496/CD
,/,
MAF/NN
=/JJ
0.11/CD
,/,
combined/JJ
p/NN
=/JJ
1.15/CD
×/CD
10-15/CD
)/)
(/(
Table/JJ
2/CD
,/,
Fig/NN
./.
====================
3B/NN
)/)
./.
====================
The/DT
associated/VBN
signal/NN
is/VBZ
concordant/JJ
with/IN
a/DT
previously/RB
published/VBN
result/NN
in/IN
the/DT
Japanese/JJ
population/NN
[/(
6/CD
]/)
./.
====================
This/DT
SNP/NN
is/VBZ
located/JJ
in/IN
the/DT
3/CD
'/``
untranslated/JJ
region/NN
(/(
UTR/NN
)/)
of/IN
SH2B/NN
adaptor/NN
protein/NN
3/CD
(/(
also/RB
known/VBN
as/IN
LNK/NN
)/)
./.
====================
SH2B3/NN
is/VBZ
a/DT
member/NN
of/IN
the/DT
APS/NN
family/NN
of/IN
adaptor/NN
proteins/NNS
,/,
which/WDT
play/VBP
a/DT
pivotal/JJ
role/NN
as/IN
broad/JJ
inhibitors/NNS
of/IN
growth/NN
factors/NNS
and/CC
cytokine/NN
signaling/NN
pathways/NNS
./.
====================
The/DT
second/JJ
SNP/NN
,/,
rs3733606/NN
(/(
MAF/NN
=/JJ
0.50/CD
,/,
combined/JJ
p/NN
=/JJ
1.46/CD
×/CD
10-10/CD
)/)
(/(
Table/JJ
2/CD
,/,
Fig/NN
./.
====================
3A/NN
)/)
in/IN
4p16/CD
,/,
is/VBZ
in/IN
the/DT
3/CD
'/``
UTR/NN
of/IN
the/DT
KIAA0232/NN
gene/NN
,/,
which/WDT
translates/VBZ
the/DT
functionally/RB
unknown/JJ
hypothetical/JJ
protein/NN
LOC9778/NN
./.
====================
The/DT
third/JJ
locus/NN
associated/VBN
with/IN
platelet/NN
is/VBZ
at/IN
6p21/NN
(/(
rs9296095/NN
,/,
MAF/NN
=/JJ
0.23/CD
,/,
combined/JJ
p/NN
=/JJ
1.67/CD
×/CD
10-7/CD
)/)
(/(
Table/JJ
2/CD
,/,
Fig/NN
./.
====================
3C/NN
)/)
./.
====================
We/PRP
performed/VBD
a/DT
GWAS/JJ
of/IN
platelet/NN
count/NN
using/VBG
352,225/CD
SNPs/NNS
profiled/VBD
with/IN
the/DT
Affymetrix/JJ
Genome-Wide/NN
human/JJ
SNP/NN
array/NN
5.0/CD
in/IN
8,842/CD
individuals/NNS
from/IN
the/DT
Anseong/JJ
and/CC
Ansan/NN
cohorts/NNS
as/IN
described/VBN
previously/RB
[/(
13/CD
]/)
./.
====================
In/IN
a/DT
two-stage/JJ
design/NN
(/(
8,842/CD
discovery/NN
and/CC
7,861/CD
replication/NN
samples/NNS
)/)
,/,
we/PRP
confirmed/VBD
three/CD
loci/NNS
associated/VBN
with/IN
platelet/NN
count/NN
at/IN
a/DT
genomewide/JJ
significance/NN
level/NN
(/(
</JJR
1.0/CD
×/CD
10-7/CD
)/)
./.
====================
Besides/RB
an/DT
unknown/JJ
functional/JJ
gene/NN
,/,
we/PRP
found/VBD
two/CD
candidate/NN
genes/NNS
,/,
SH2B3/NN
and/CC
BAK1/NN
,/,
responsible/JJ
for/IN
the/DT
variation/NN
in/IN
platelet/NN
counts/NNS
./.
====================
These/DT
genes/NNS
are/VBP
potential/JJ
candidates/NNS
for/IN
affecting/VBG
platelet/NN
count/NN
./.
====================
Lymphocyte/NN
adapter/NN
protein/NN
(/(
SH2B3/NN
,/,
also/RB
known/VBN
as/IN
LNK/NN
)/)
is/VBZ
expressed/VBN
in/IN
hematopoietic/JJ
precursor/NN
cells/NNS
and/CC
in/IN
endothelial/JJ
cells/NNS
and/CC
is/VBZ
known/VBN
to/TO
be/VB
involved/VBN
in/IN
inflammation/NN
[/(
18/CD
]/)
./.
====================
LNK-deficient/JJ
mice/NNS
show/VBP
a/DT
marked/JJ
difference/NN
of/IN
hematopoiesis/NN
,/,
accompanying/VBG
increased/VBD
numbers/NNS
of/IN
various/JJ
types/NNS
of/IN
cells/NNS
,/,
such/JJ
as/IN
megakaryocytes/NNS
,/,
B/NN
lymphoid/JJ
,/,
erythroid/JJ
progenitor/NN
,/,
and/CC
hematopoietic/JJ
stem/NN
cells/NNS
[/(
19/CD
]/)
./.
====================
Several/JJ
SNPs/NNS
within/IN
the/DT
SH2B3/NN
region/NN
are/VBP
well/RB
known/VBN
as/IN
variants/NNS
associated/VBN
with/IN
blood/NN
pressure/NN
,/,
myocardial/JJ
infarction/NN
,/,
type/NN
1/CD
diabetes/VBZ
,/,
and/CC
celiac/JJ
disease/NN
[/(
20/CD
]/)
./.
====================
BAK1/NN
,/,
a/DT
multidomain/JJ
pro-apoptotic/JJ
family/NN
member/NN
,/,
has/VBZ
shown/VBN
to/TO
be/VB
involved/VBN
in/IN
apoptotic/JJ
cell/NN
death/NN
,/,
playing/VBG
a/DT
role/NN
as/IN
an/DT
essential/JJ
mediator/NN
[/(
21/CD
,/,
22/CD
,/,
23/CD
,/,
24/CD
]/)
./.
====================
Kamatani/NN
et/FW
al/JJ
./.
====================
[/(
6/CD
]/)
reported/VBD
that/IN
BAK1/NN
is/VBZ
a/DT
putative/JJ
strong/JJ
candidate/NN
gene/NN
accounting/VBG
for/IN
numbers/NNS
of/IN
platelets/NNS
./.
====================
This/DT
SNP/NN
is/VBZ
located/JJ
in/IN
the/DT
4th/NN
intron/NN
in/IN
BAK1/NN
(/(
Bcl2-antagonist/killer1/NN
)/)
,/,
which/WDT
encodes/VBZ
a/DT
protein/NN
acting/VBG
as/IN
a/DT
strong/JJ
proapoptotic/JJ
effector/NN
that/DT
is/VBZ
known/VBN
to/TO
control/JJ
platelet/NN
lifespan/NN
[/(
25/CD
]/)
./.
====================
The/DT
intrinsic/JJ
machinery/NN
for/IN
apoptosis/NN
regulates/VBZ
the/DT
life/NN
span/NN
of/IN
anucleate/JJ
platelets/NNS
[/(
25/CD
]/)
./.
====================
KIAA0232/NN
has/VBZ
no/DT
known/JJ
biological/JJ
function/NN
and/CC
no/DT
clue/NN
for/IN
a/DT
related/JJ
biological/JJ
pathway/NN
./.
====================
Given/IN
the/DT
weak/JJ
linkage/NN
disequilibrium/NN
block/VBP
around/IN
KIAA0232/NN
,/,
further/RBR
investigation/NN
is/VBZ
required/VBN
for/IN
the/DT
biological/JJ
function/NN
./.
====================
Some/DT
studies/NNS
have/VBP
discovered/VBN
genetic/JJ
factors/NNS
associated/VBN
with/IN
platelet/NN
count/NN
through/IN
genome-wide/NN
associated/VBN
studies/NNS
across/IN
diverse/JJ
ethnic/JJ
groups/NNS
[/(
12/CD
,/,
26/CD
]/)
./.
====================
Qayyum/NN
et/FW
al/JJ
./.
====================
[/(
12/CD
]/)
reported/VBD
that/IN
a/DT
candidate/NN
gene/NN
,/,
BAK1/NN
,/,
was/VBD
significant/JJ
in/IN
African-Americans/NNS
./.
====================
Also/RB
,/,
Shameer/NN
et/FW
al/JJ
./.
====================
[/(
26/CD
]/)
reported/VBD
that/IN
SH2B3/NN
and/CC
KIAA0232/NN
in/IN
European/JJ
ancestry/NN
were/VBD
also/RB
significant/JJ
in/IN
platelet/NN
count/NN
and/CC
mean/JJ
platelet/NN
volume/NN
,/,
respectively/RB
./.
====================
Numerous/JJ
previous/JJ
studies/NNS
have/VBP
demonstrated/VBN
the/DT
association/NN
between/IN
platelet/NN
counts/NNS
and/CC
various/JJ
phenotypes/NNS
in/IN
human/JJ
and/CC
mice/NNS
[/(
27/CD
]/)
./.
====================
The/DT
Atherosclerosis/NN
Risk/NN
in/IN
Community/NN
(/(
ARIC/NN
)/)
study/NN
has/VBZ
shown/VBN
that/IN
platelet/NN
counts/NNS
are/VBP
positively/RB
correlated/VBD
with/IN
leukocytes/NNS
[/(
28/CD
]/)
./.
====================
Turakhia/NN
et/FW
al/JJ
./.
====================
[/(
29/CD
]/)
also/RB
reported/VBD
the/DT
association/NN
between/IN
higher/JJR
platelet/NN
counts/NNS
and/CC
residual/JJ
thrombus/NN
after/IN
fibrinolytic/JJ
therapy/NN
,/,
which/WDT
is/VBZ
in/IN
agreement/NN
with/IN
the/DT
ARIC/NN
study/NN
./.
====================
The/DT
evidence/NN
of/IN
a/DT
relationship/NN
between/IN
platelet/NN
count/NN
and/CC
insulin/NN
resistance/NN
in/IN
non-obese/JJ
type/NN
2/CD
diabetic/JJ
patients/NNS
was/VBD
reported/VBN
from/IN
a/DT
study/NN
on/IN
Japanese/JJ
[/(
30/CD
]/)
./.
====================
The/DT
number/NN
of/IN
platelets/NNS
is/VBZ
also/RB
a/DT
possible/JJ
predictor/NN
of/IN
the/DT
risk/NN
of/IN
death/NN
and/CC
cardiovascular/JJ
disease/NN
[/(
31/CD
]/)
./.
====================
In/IN
conclusion/NN
,/,
we/PRP
identified/VBD
and/CC
validated/VBD
common/JJ
variants/NNS
at/IN
1/CD
novel/JJ
locus/NN
,/,
BAK1/NN
,/,
and/CC
2/CD
known/VBN
variants/NNS
,/,
SH2B/NN
and/CC
KIAA0232/NN
,/,
responsible/JJ
for/IN
the/DT
variation/NN
of/IN
platelet/NN
counts/NNS
in/IN
population-based/JJ
cohorts/NNS
./.
====================
Our/PRP$
research/NN
demonstrates/VBZ
the/DT
results/NNS
from/IN
a/DT
meta-analysis/NN
and/CC
follow-up/JJ
genotyping/VBG
to/TO
retrieve/VB
positive/JJ
evidence/NN
for/IN
the/DT
association/NN
of/IN
3/CD
loci/NNS
with/IN
platelet/NN
counts/NNS
./.
====================
In/IN
addition/NN
,/,
fine/JJ
mapping/NN
and/CC
functional/JJ
studies/NNS
on/IN
the/DT
discovered/JJ
loci/NNS
will/MD
help/VB
us/PRP
understand/VB
the/DT
hidden/JJ
physiological/JJ
mechanisms/NNS
underlying/VBG
platelet/NN
count/NN
./.
====================
Quantile-quantile/JJ
plot/NN
for/IN
platelet/NN
count/NN
./.
====================
The/DT
observed/VBN
p-values/NNS
(/(
y/RB
axis/NN
)/)
were/VBD
compared/VBN
with/IN
the/DT
expected/VBN
p-values/NNS
under/IN
the/DT
null/JJ
distribution/NN
(/(
x/NN
axis/NN
)/)
for/IN
each/DT
trait/VBP
./.
====================
The/DT
shaded/JJ
region/NN
represents/VBZ
the/DT
95/CD
%/NN
concentration/NN
band/NN
./.
====================
Chromosome/NN
plot/NN
for/IN
platelet/NN
counts/NNS
./.
====================
Genome-wide/NN
association/NN
study/NN
for/IN
log-transformed/JJ
platelet/NN
count/NN
on/IN
a/DT
population-based/JJ
sample/NN
of/IN
8,842/CD
individuals/NNS
from/IN
the/DT
Korea/NN
Association/NN
Resource/NN
(/(
KARE/NN
)/)
study/NN
./.
====================
The/DT
x/NN
axis/NN
represents/VBZ
the/DT
genomic/JJ
position/NN
(/(
in/IN
Gb/NN
)/)
of/IN
352,225/CD
single/JJ
nucleotide/NN
polymorphisms/NNS
;/:
they/PRP
show/VBP
-log10/CD
(/(
p-value/NN
)/)
./.
====================
Single/JJ
nucleotide/NN
polymorphisms/NNS
with/IN
a/DT
p-value/JJ
</JJR
1/CD
×/NN
10-4/CD
are/VBP
highlighted/VBN
in/IN
red/JJ
./.
====================
Regional/JJ
plot/NN
of/IN
three/CD
discovered/VBN
variants/NNS
./.
====================
(/(
A-C/NN
)/)
p-value/JJ
plots/NNS
showing/VBG
the/DT
association/NN
signals/NNS
in/IN
the/DT
region/NN
of/IN
KIAA0232/NN
on/IN
chromosome/NN
4/CD
(/(
A/DT
)/)
,/,
SH2B3/NN
on/IN
chromosome/NN
12/CD
(/(
B/NN
)/)
,/,
and/CC
BAK1/NN
on/IN
chromosome/NN
6/CD
(/(
C/NN
)/)
./.
====================
In/IN
the/DT
top/NN
panel/NN
,/,
the/DT
association/NN
signals/NNS
scaled/VBD
by/IN
-log10/CD
(/(
p-value/JJ
)/)
(/(
typed/VBN
or/CC
imputed/JJ
SNPs/NNS
)/)
at/IN
each/DT
locus/NN
are/VBP
distributed/VBN
in/IN
a/DT
genomic/JJ
region/NN
500/CD
kb/NN
to/TO
either/CC
side/JJ
of/IN
the/DT
lead/NN
association/NN
signal/NN
(/(
typed/VBN
)/)
./.
====================
Each/DT
SNP/NN
is/VBZ
plotted/VBN
as/IN
a/DT
circle/JJ
along/IN
the/DT
chromosomal/JJ
position/NN
,/,
and/CC
linkage/NN
disequilibrium/NN
between/IN
the/DT
lead/JJ
SNP/NN
and/CC
the/DT
other/JJ
SNPs/NNS
is/VBZ
colored/VBN
as/IN
a/DT
scale/JJ
from/IN
low/JJ
(/(
blue/JJ
)/)
to/TO
high/JJ
(/(
red/JJ
)/)
or/CC
is/VBZ
colored/VBN
gray/JJ
if/IN
linkage/NN
disequilibrium/NN
information/NN
was/VBD
not/RB
available/JJ
in/IN
the/DT
1,000/CD
genomes/NNS
June/JJ
2010/CD
CHB+JPT/NN
samples/NNS
./.
====================
The/DT
lead/NN
SNP/NN
is/VBZ
colored/VBN
purple/JJ
diamond/JJ
,/,
and/CC
the/DT
overall/JJ
meta-analysis/NN
result/NN
is/VBZ
shown/VBN
with/IN
a/DT
purple/JJ
circle/NN
./.
====================
The/DT
recombination/NN
rate/NN
estimated/VBN
from/IN
HapMap/NN
phase/NN
2/CD
is/VBZ
plotted/VBN
in/IN
blue/JJ
./.
====================
The/DT
bottom/CC
panel/NN
illustrates/VBZ
the/DT
locations/NNS
of/IN
known/VBN
genes/NNS
./.
====================
Genetic/JJ
information/NN
is/VBZ
based/VBN
on/IN
NCBI/NN
build/JJ
36/CD
and/CC
dbSNP/NN
build/JJ
130/CD
./.
====================
SNP/NN
,/,
single-nucleotide/JJ
polymorphism/NN
;/:
CHB/NN
,/,
Han/JJ
Chinese/JJ
in/IN
Beijing/JJ
,/,
China/NN
;/:
JPT/NN
,/,
Japanese/JJ
in/IN
Tokyo/NN
,/,
Japan/NNP
./.
====================
Samples/NNS
used/VBN
in/IN
this/DT
study/NN
====================
Variants/NNS
that/DT
associate/VBP
with/IN
variation/NN
in/IN
platelet/NN
counts/NNS
====================
